Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance.

Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic β-cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

[1]  N. Fujii,et al.  Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle , 2010, Proceedings of the National Academy of Sciences.

[2]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[3]  K. Petersen,et al.  Lipid-induced insulin resistance: unravelling the mechanism , 2010, The Lancet.

[4]  R. Salgia,et al.  Fyn: a novel molecular target in cancer. , 2010, Cancer.

[5]  P. Aschner.  Metabolic syndrome as a risk factor for diabetes , 2010, Expert review of cardiovascular therapy.

[6]  J. Pessin,et al.  Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1. , 2010, Cell metabolism.

[7]  A. Hevener,et al.  AMPK β1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance* , 2009, The Journal of Biological Chemistry.

[8]  B. Kemp,et al.  AMPK in Health and Disease. , 2009, Physiological reviews.

[9]  F. Wondisford,et al.  Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding Protein , 2009, Cell.

[10]  M. Zou,et al.  Identification of the Serine 307 of LKB1 as a Novel Phosphorylation Site Essential for Its Nucleocytoplasmic Transport and Endothelial Cell Angiogenesis , 2009, Molecular and Cellular Biology.

[11]  J. Zierath,et al.  Hunting for the SNARK in metabolic disease. , 2009, American journal of physiology. Endocrinology and metabolism.

[12]  Stefano Caserta,et al.  T‐cell receptor proximal signaling via the Src‐family kinases, Lck and Fyn, influences T‐cell activation, differentiation, and tolerance , 2009, Immunological reviews.

[13]  D. Hardie,et al.  C-terminal Phosphorylation of LKB1 Is Not Required for Regulation of AMP-activated Protein Kinase, BRSK1, BRSK2, or Cell Cycle Arrest* , 2009, Journal of Biological Chemistry.

[14]  N. Ruderman,et al.  SIRT1 Modulation of the Acetylation Status, Cytosolic Localization, and Activity of LKB1 , 2008, Journal of Biological Chemistry.

[15]  D. Hardie,et al.  AMPK: a key regulator of energy balance in the single cell and the whole organism , 2008, International Journal of Obesity.

[16]  I. Bahar,et al.  Structure and dynamic regulation of Src-family kinases , 2008, Cellular and Molecular Life Sciences.

[17]  T. Ochiya,et al.  Susceptibility of Snark‐deficient mice to azoxymethane‐induced colorectal tumorigenesis and the formation of aberrant crypt foci , 2008, Cancer science.

[18]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[19]  G. Rutter,et al.  Inhibition of AMP-Activated Protein Kinase Protects Pancreatic β-Cells From Cytokine-Mediated Apoptosis and CD8+ T-Cell–Induced Cytotoxicity , 2008, Diabetes.

[20]  U. Stochaj,et al.  Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK-->ERK1/2 pathway. , 2007, American journal of physiology. Cell physiology.

[21]  G. Barsh,et al.  AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. , 2007, The Journal of clinical investigation.

[22]  J. Pessin,et al.  Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the SRC kinase family member Fyn. , 2007, Cell metabolism.

[23]  P. Schjerling,et al.  Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. , 2007, American journal of physiology. Endocrinology and metabolism.

[24]  S. Okamoto,et al.  Leptin Stimulates Fatty Acid Oxidation and Peroxisome Proliferator-Activated Receptor α Gene Expression in Mouse C2C12 Myoblasts by Changing the Subcellular Localization of the α2 Form of AMP-Activated Protein Kinase , 2007, Molecular and Cellular Biology.

[25]  M. Birnbaum,et al.  The Role of AMPK and mTOR in Nutrient Sensing in Pancreatic β-Cells* , 2007, Journal of Biological Chemistry.

[26]  F. Pralong,et al.  Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. , 2007, Endocrinology.

[27]  S. Yusuf,et al.  The DREAM trial – Authors' reply , 2006, The Lancet.

[28]  Michael D. Schneider,et al.  A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway , 2006, Proceedings of the National Academy of Sciences.

[29]  G. Rutter,et al.  Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity , 2006, Diabetologia.

[30]  Uwe Riek,et al.  Dissecting the Role of 5′-AMP for Allosteric Stimulation, Activation, and Deactivation of AMP-activated Protein Kinase* , 2006, Journal of Biological Chemistry.

[31]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[32]  M. Carlson,et al.  Mammalian TAK1 Activates Snf1 Protein Kinase in Yeast and Phosphorylates AMP-activated Protein Kinase in Vitro* , 2006, Journal of Biological Chemistry.

[33]  Y. Uchijima,et al.  Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. , 2006, Diabetes research and clinical practice.

[34]  B. Kahn,et al.  Diet-induced Obesity Alters AMP Kinase Activity in Hypothalamus and Skeletal Muscle* , 2006, Journal of Biological Chemistry.

[35]  D. Hardie,et al.  AMP‐activated protein kinase – development of the energy sensor concept , 2006, The Journal of physiology.

[36]  Kei Sakamoto,et al.  LKB1-dependent signaling pathways. , 2006, Annual review of biochemistry.

[37]  N. Musi.  AMP-activated protein kinase and type 2 diabetes. , 2006, Current medicinal chemistry.

[38]  Min-Seon Kim,et al.  AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. , 2006, Biochemical and biophysical research communications.

[39]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[40]  N. Fujii,et al.  AMP-activated Protein Kinase α2 Activity Is Not Essential for Contraction- and Hyperosmolarity-induced Glucose Transport in Skeletal Muscle* , 2005, Journal of Biological Chemistry.

[41]  Xin-Yun Huang,et al.  Requirement of SRC-family tyrosine kinases in fat accumulation. , 2005, Biochemistry.

[42]  M. Prentki,et al.  AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. , 2005, American journal of physiology. Endocrinology and metabolism.

[43]  M. Goodarzi,et al.  Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents , 2005, Diabetes, obesity & metabolism.

[44]  M. Montminy,et al.  The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism , 2005, Nature.

[45]  A. Means,et al.  The Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase Kinases* , 2005, Journal of Biological Chemistry.

[46]  D. Hardie,et al.  Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase* , 2005, Journal of Biological Chemistry.

[47]  A. Edelman,et al.  Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. , 2005, Cell metabolism.

[48]  Kei Sakamoto,et al.  Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction , 2005, The EMBO journal.

[49]  B. Viollet,et al.  Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. , 2005, Diabetes.

[50]  A. Saltiel,et al.  The Stomatin/Prohibitin/Flotillin/HflK/C Domain of Flotillin-1 Contains Distinct Sequences That Direct Plasma Membrane Localization and Protein Interactions in 3T3-L1 Adipocytes* , 2005, Journal of Biological Chemistry.

[51]  N. Fujii,et al.  Long-term AICAR administration and exercise prevents diabetes in ZDF rats. , 2005, Diabetes.

[52]  Laura Conner,et al.  Biochemical Regulation of Mammalian AMP-activated Protein Kinase Activity by NAD and NADH* , 2004, Journal of Biological Chemistry.

[53]  D. Hardie.  The AMP-activated protein kinase pathway – new players upstream and downstream , 2004, Journal of Cell Science.

[54]  Arthur Weiss,et al.  Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation , 2004, Oncogene.

[55]  B. Viollet,et al.  Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. , 2004, Diabetes.

[56]  D. Hardie,et al.  Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. , 2004, American journal of physiology. Endocrinology and metabolism.

[57]  M. Birnbaum,et al.  AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus , 2004, Nature.

[58]  D. Carling,et al.  AMP-activated Protein Kinase Plays a Role in the Control of Food Intake* , 2004, Journal of Biological Chemistry.

[59]  Lewis C Cantley,et al.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Peter Schjerling,et al.  Knockout of the α2 but Not α1 5′-AMP-activated Protein Kinase Isoform Abolishes 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranosidebut Not Contraction-induced Glucose Uptake in Skeletal Muscle* , 2004, Journal of Biological Chemistry.

[61]  B. Kemp.  Faculty Opinions recommendation of Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. , 2003 .

[62]  Jérôme Boudeau,et al.  Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[63]  M. Prentki,et al.  Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. , 2003, Endocrinology.

[64]  M. Prentki,et al.  AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. , 2003, Acta physiologica Scandinavica.

[65]  H C Clevers,et al.  Activation of the tumour suppressor kinase LKB1 by the STE20‐like pseudokinase STRAD , 2003, The EMBO journal.

[66]  G. Rutter,et al.  Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. , 2003, The Biochemical journal.

[67]  D. Pipeleers,et al.  AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. , 2003, Journal of molecular endocrinology.

[68]  J. W. Rush,et al.  AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. , 2003, American journal of physiology. Endocrinology and metabolism.

[69]  D. Pipeleers,et al.  AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase , 2003, Diabetologia.

[70]  H. Lodish,et al.  Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl–CoA carboxylase inhibition and AMP-activated protein kinase activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  T. Atkinson,et al.  Identification of an alternatively spliced isoform of the fyn tyrosine kinase. , 2002, Biochemical and biophysical research communications.

[72]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[73]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[74]  D. Olive,et al.  Cutting Edge: Recruitment of the Ancestral fyn Gene During Emergence of the Adaptive Immune System1 , 2002, Journal of Immunology.

[75]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[76]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[77]  G. Sapkota,et al.  Phosphorylation of the Protein Kinase Mutated in Peutz-Jeghers Cancer Syndrome, LKB1/STK11, at Ser431 by p90RSK and cAMP-dependent Protein Kinase, but Not Its Farnesylation at Cys433, Is Essential for LKB1 to Suppress Cell Growth* , 2001, The Journal of Biological Chemistry.

[78]  M. Bucan,et al.  A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. , 2001, Molecular cell.

[79]  P. Stein,et al.  A Unique Role for Fyn in CNS Myelination , 2001, The Journal of Neuroscience.

[80]  B. Kemp,et al.  Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. , 2001, The Biochemical journal.

[81]  D. Carling,et al.  Characterization of the Role of AMP-Activated Protein Kinase in the Regulation of Glucose-Activated Gene Expression Using Constitutively Active and Dominant Negative Forms of the Kinase , 2000, Molecular and Cellular Biology.

[82]  D. Hardie,et al.  5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. , 2000, Diabetes.

[83]  D. Carling,et al.  The regulation of AMP-activated protein kinase by phosphorylation. , 2000, The Biochemical journal.

[84]  M. Uhler,et al.  LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. , 2000, The Biochemical journal.

[85]  B. Kemp,et al.  Expression of the AMP‐activated protein kinase β1 and β2 subunits in skeletal muscle , 1999 .

[86]  L. Goodyear,et al.  5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. , 1999, Diabetes.

[87]  G. Shulman,et al.  Effect of AMPK activation on muscle glucose metabolism in conscious rats. , 1999, American journal of physiology. Endocrinology and metabolism.

[88]  M. Yanagisawa,et al.  ETB receptor activation leads to activation and phosphorylation of NHE3. , 1999, American journal of physiology. Cell physiology.

[89]  B. Kemp,et al.  Cellular Distribution and Developmental Expression of AMP‐Activated Protein Kinase Isoforms in Mouse Central Nervous System , 1999, Journal of neurochemistry.

[90]  S. Anderson,et al.  Fyn Associates with Cbl and Phosphorylates Tyrosine 731 in Cbl, A Binding Site for Phosphatidylinositol 3-Kinase* , 1999, The Journal of Biological Chemistry.

[91]  Y. Minokoshi,et al.  Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats , 1998, Neuroscience Research.

[92]  A. Edelman,et al.  Components of a Calmodulin-dependent Protein Kinase Cascade , 1998, The Journal of Biological Chemistry.

[93]  D. Hardie,et al.  AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. , 1998, The Biochemical journal.

[94]  A. Prescott,et al.  AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. , 1998, The Biochemical journal.

[95]  I. Leclerc,et al.  The 5′‐AMP‐activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex , 1998, FEBS letters.

[96]  D. Carling,et al.  AMP-activated Protein Kinase Inhibits the Glucose-activated Expression of Fatty Acid Synthase Gene in Rat Hepatocytes* , 1998, The Journal of Biological Chemistry.

[97]  C. Thornton,et al.  Identification of a Novel AMP-activated Protein Kinase β Subunit Isoform That Is Highly Expressed in Skeletal Muscle* , 1998, The Journal of Biological Chemistry.

[98]  D. Hardie,et al.  AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. , 1997, American journal of physiology. Endocrinology and metabolism.

[99]  R. Burcelin,et al.  Acute stimulation of glucose metabolism in mice by leptin treatment , 1997, Nature.

[100]  A. Saltiel,et al.  Insulin-stimulated Tyrosine Phosphorylation of Caveolin Is Specific for the Differentiated Adipocyte Phenotype in 3T3-L1 Cells* , 1997, The Journal of Biological Chemistry.

[101]  J. McGarry,et al.  The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. , 1997, European journal of biochemistry.

[102]  J. C. Parrish,et al.  Synergy in Protein Engineering , 1996, The Journal of Biological Chemistry.

[103]  M. White,et al.  The Fyn Tyrosine Kinase Binds Irs-1 and Forms a Distinct Signaling Complex during Insulin Stimulation (*) , 1996, The Journal of Biological Chemistry.

[104]  J. Scott,et al.  Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. , 1996, The Journal of biological chemistry.

[105]  B. Kemp,et al.  Mammalian AMP-activated Protein Kinase Subfamily (*) , 1996, The Journal of Biological Chemistry.

[106]  D. Hardie,et al.  The AMP‐activated Protein Kinase Gene is Highly Expressed in Rat Skeletal Muscle , 1995 .

[107]  J. Scott,et al.  The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle. Alternative splicing and tissue distribution of the mRNA. , 1995, European journal of biochemistry.

[108]  B. Kemp,et al.  Mammalian 5'-AMP-activated protein kinase non-catalytic subunits are homologs of proteins that interact with yeast Snf1 protein kinase. , 1994, The Journal of biological chemistry.

[109]  P. Brickell,et al.  src‐related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells , 1994, FEBS letters.

[110]  J. Scott,et al.  Yeast SNF1 is functionally related to mammalian AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo. , 1994, The Journal of biological chemistry.

[111]  M. Resh,et al.  Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. , 1994, The Journal of biological chemistry.

[112]  B. Sefton,et al.  Role of tyrosine kinases in lymphocyte activation. , 1994, Current opinion in immunology.

[113]  K. Semba,et al.  Functional and physical interaction of protein-tyrosine kinases Fyn and Csk in the T-cell signaling system. , 1993, The Journal of biological chemistry.

[114]  L. Witters,et al.  Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. , 1993, The Journal of biological chemistry.

[115]  H. Greulich,et al.  A novel Yes-related kinase, Yrk, is expressed at elevated levels in neural and hematopoietic tissues. , 1993, Oncogene.

[116]  Cook Mp,et al.  Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. , 1989 .

[117]  G. Cook,et al.  Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. , 1987, The Journal of biological chemistry.

[118]  R. Pratley,et al.  Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[119]  Louise Lantier,et al.  AMPK: Lessons from transgenic and knockout animals. , 2009, Frontiers in bioscience.

[120]  M. Kirby,et al.  Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. , 2009, Clinical science.

[121]  C. Polge,et al.  SNF1/AMPK/SnRK1 kinases, global regulators at the heart of energy control? , 2007, Trends in plant science.

[122]  D. Pipeleers,et al.  Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation. , 2007, Free radical biology & medicine.

[123]  M. Birnbaum,et al.  The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. , 2007, The Journal of biological chemistry.

[124]  Roy J Martin,et al.  Role of neuronal energy status in the regulation of adenosine 5'-monophosphate-activated protein kinase, orexigenic neuropeptides expression, and feeding behavior. , 2005, Endocrinology.

[125]  B. Viollet,et al.  Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. , 2004, The Journal of biological chemistry.

[126]  B. Viollet,et al.  The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. , 2003, The Journal of clinical investigation.

[127]  B. Kemp,et al.  Expression of the AMP-activated protein kinase beta1 and beta2 subunits in skeletal muscle. , 1999, FEBS letters.

[128]  J. Nezu,et al.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. , 1998, Nature genetics.

[129]  Darryl Shibata,et al.  Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis , 1997, Nature Genetics.

[130]  R. Perlmutter,et al.  Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. , 1989, The New biologist.